Using the liver to boost immune treatments for pancreatic cancer
Targeting the liver for immunotherapy in pancreatic cancer
This work looks at how the liver's reaction to pancreatic tumors might be used to help immune-based treatments work better for people with pancreatic cancer, especially when cancer has spread to the liver.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11234286 on NIH RePORTER |
What this research studies
Researchers are studying how pancreatic tumors send signals that activate liver cells to release proteins and recruit immune and support cells, creating an environment that can block immune therapies. They will combine laboratory models with patient-derived samples to identify the liver factors and immune pathways involved. The team aims to test strategies that reverse or block those liver-driven changes so T cells can better attack tumors. Successful findings could point toward new combination approaches that pair liver-targeted interventions with existing immunotherapies.
Who could benefit from this research
Good fit: People with pancreatic cancer—particularly those with liver metastases or at high risk of liver spread—are the most relevant candidates for this line of research.
Not a fit: People whose pancreatic cancer has not involved the liver or who are receiving non-immune-based therapies may be less likely to see direct benefits from this research.
Why it matters
Potential benefit: If successful, this work could make immunotherapies more effective for people with pancreatic cancer that involves the liver, expanding treatment options and potentially improving outcomes.
How similar studies have performed: Early studies have suggested the liver can blunt immune responses to cancer and targeting liver-driven immune changes is a relatively new approach with promising but still preliminary results.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Beatty, Gregory L — University of Pennsylvania
- Study coordinator: Beatty, Gregory L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.